Publication Date
| In 2026 | 0 |
| Since 2025 | 0 |
| Since 2022 (last 5 years) | 0 |
| Since 2017 (last 10 years) | 1 |
| Since 2007 (last 20 years) | 1 |
Descriptor
| Autism | 1 |
| Behavior Modification | 1 |
| Behavior Problems | 1 |
| Caregivers | 1 |
| Child Behavior | 1 |
| Drug Therapy | 1 |
| Genetic Disorders | 1 |
| Pervasive Developmental… | 1 |
| Quality of Life | 1 |
| Sleep | 1 |
Source
| Journal of Autism and… | 1 |
Author
| Breddy, John | 1 |
| Findling, Robert L. | 1 |
| Gringras, Paul | 1 |
| Malow, Beth A. | 1 |
| Maras, Athanasios | 1 |
| Melmed, Raun D. | 1 |
| Nir, Tali | 1 |
| Schroder, Carmen M. | 1 |
| Shahmoon, Shiri | 1 |
| Zisapel, Nava | 1 |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Strengths and Difficulties… | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkSchroder, Carmen M.; Malow, Beth A.; Maras, Athanasios; Melmed, Raun D.; Findling, Robert L.; Breddy, John; Nir, Tali; Shahmoon, Shiri; Zisapel, Nava; Gringras, Paul – Journal of Autism and Developmental Disorders, 2019
A randomized, 13-weeks, placebo-controlled double-blind study in 125 subjects aged 2-17.5 years with Autism Spectrum Disorder or Smith-Magenis syndrome and insomnia demonstrated efficacy and safety of easily-swallowed prolonged-release melatonin mini-tablets (PedPRM; 2-5 mg) in improving sleep duration and onset. Treatment effects on child…
Descriptors: Autism, Pervasive Developmental Disorders, Genetic Disorders, Sleep
